Valneva

Valneva Current Liabilities

The Current Liabilities of Valneva (VLA.PA) as of Oct 9, 2026 is 85.99 M EUR. In the previous year, Current Liabilities was 169.18 M EUR — a change of -49.17% (lower).

Current Liabilities

85.99 MEUR

YoY

-49.17%

Last updated:

Current Liabilities of Valneva is 2025 85.99 M EUR. Current Liabilities of Valneva was 2024 169.18 M EUR. It decreases by -49.17% lower compared to the previous year.

The Valneva Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
70.18 M EUR
Jan 1, 2019
61.47 M EUR
Jan 1, 2020
120.45 M EUR
Jan 1, 2021
324.45 M EUR
Jan 1, 2022
331.43 M EUR
Jan 1, 2023
242.44 M EUR
Jan 1, 2024
169.18 M EUR
Jan 1, 2025
85.99 M EUR
The Valneva Current Liabilities history
YEARCurrent LiabilitiesYoY
85.99 MEUR-49.17%
169.18 MEUR-30.22%
242.44 MEUR-26.85%
331.43 MEUR+2.15%
324.45 MEUR+169.36%
120.45 MEUR+95.95%
61.47 MEUR-12.41%
70.18 MEUR+9.29%
64.22 MEUR-0.51%
64.54 MEUR-15.07%
76.00 MEUR+93.27%
39.32 MEUR-0.15%
39.38 MEUR+212.85%
12.59 MEUR-2.16%
12.87 MEUR-9.27%
14.18 MEUR+76.75%
8.02 MEUR+17.47%
6.83 MEUR+51.47%
4.51 MEUR+20.08%
3.76 MEUR-2.47%
3.85 MEUR+158.56%
1.49 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Current Liabilities of Valneva is 85.99 M EUR in 2025.

Current Liabilities of Valneva changed from 169.18 M EUR to 85.99 M EUR, representing a -49.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Valneva since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Valneva historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Valneva

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Valneva